Chargement de l’entreprise
Keep exploring
The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,35T $USA+
JNJJohnson & Johnson682,6B $USA+
MRKMerck & Co., Inc.362,2B $USA
AMGNAmgen Inc.252,6B $USA+
GILDGilead Sciences, Inc.208,3B $USA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
BIIBBiogen Inc.28 oct. 2026BAGraded B, now A
Comment elle gagne de l'argent
- Prescription medicines
En concurrence avec
Ce qu'elle vend6
Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.
Afficher 3 de plus
Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.
Qui l'achète5
- Drug wholesalers buy medicines for resale to pharmacies and healthcare providers.
- Retail and specialty pharmacies dispense medicines to patients, including drugs that need special handling.
- Hospitals and private health systems buy medicines for treatment in their facilities.
Afficher 2 de plus
- Government agencies and government-supported health systems buy or fund medicines for patients.
- Insurers and managed-care organizations influence which medicines are covered and reimbursed.
Sur quoi elle repose, et ce qui pourrait la briser
Ce dont l'activité dépend
- 1Sales of branded medicines depend on patent rights and regulatory exclusivity; generic or biosimilar competitors can enter after protections expire or are successfully challenged.
- 2Some medicines depend on licenses, collaborations or other agreements with outside drug developers.
- 3Manufacturing depends on specialized materials and tightly controlled production processes; some products may have limited alternative suppliers.
- 4Access to medicines depends on health-authority approval and on insurers or government health systems deciding whether and how much to reimburse.
Ce qui pourrait mal tourner
- 1Generic competition and patent challenges can reduce sales when drug protections expire or competitors successfully challenge them; Novartis has also faced generic erosion for established medicines.
- 2Government price controls, Medicare price negotiations, required rebates and insurer coverage decisions can limit the prices Novartis receives or restrict patient access.
- 3Drug candidates can fail clinical trials or fail to receive approval after years of research and testing, leaving Novartis without a marketable medicine and with development costs already incurred.
À propos de Novartis AG
Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).
- Siège
- Basel, Switzerland
- Fondée en
- 1996
- Effectif
- 75,267 (December 31, 2025, high)
- Cotée sur
- NYSE
- Clôture de l'exercice
- December 31
Construit à partir des documents déposés par Novartis AG auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.